CASE STUDY
PAYER VALUE PROPOSITION
During the COVID-19 pandemic, a client developed an mRNA vaccine and received Emergency Use Authorization (EUA). In anticipation of the world transitioning out of the public health emergency phase, the client needed to create the payer value proposition (PVP). The purpose of the PVP is to present evidence-based clinical and economic attributes relative to competitors to demonstrate the vaccine’s necessity and ensure market access.
ACTION
Health Market Experts outlined and created a slide deck demonstrating the Unmet Need, Burden of Illness, Effectiveness, Safety, Protection against Variants, impact on Quality of Life, Economic Value, and Benefit to children and adolescents. We conducted a literature review to gather evidence and avoid inference. We refined and supported the client’s value proposition with new value messages and evidence in the form of statements, data, and the visualization of data. Health Market Experts led virtual workshops with internal stakeholders to validate messages, source data and references, and ensure cross-functional alignment on product value to support local market access discussions.
RESULT
The global PVP will be updated and adapted locally and used in market access discussions with payers for commercialization.
DOMAIN
Health Economics and Outcomes Research (HEOR)
Market Access
F50 Global Pharmaceutical Company